This announcement is a separate document:
ゼリア新薬工業：Tillotts PharmaとTVM Capital Life Scienceが潰瘍性大腸炎に対する経口抗体療法開発を目的としてMage Biologicsを設立することを発表
Zeria Pharmaceutical: Tillotts Pharma and TVM Capital Life Science announce they will establish Mage Biologics for the purpose of developing oral antibody therapy against ulcerative colitis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.